Photo from wikipedia
Key Points • Long-term deferiprone therapy was not associated with new safety concerns in patients with SCD or other anemias.• Long-term deferiprone therapy led to continued and progressive reduction in… Click to show full abstract
Key Points • Long-term deferiprone therapy was not associated with new safety concerns in patients with SCD or other anemias.• Long-term deferiprone therapy led to continued and progressive reduction in iron load in patients with SCD or other anemias.
Keywords:
iron overload;
transfusional iron;
overload sickle;
iron;
deferiprone transfusional;
sickle cell
Journal Title: Blood Advances
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Blood Advances
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!